Understanding Gestational Diabetes: A Growing Concern

Gestational diabetes mellitus (GDM) affects approximately 7 to 10 percent of pregnancies globally, making it one of the most common metabolic disorders encountered during pregnancy. The condition arises when hormonal changes from the placenta impair insulin action, leading to hyperglycemia. Risk factors include maternal age over 25, pre-pregnancy obesity, family history of type 2 diabetes, polycystic ovary syndrome, and prior GDM or macrosomic infant. Diagnosis typically occurs between 24 and 28 weeks of gestation via an oral glucose tolerance test (OGTT).

If left unmanaged, GDM increases the risk of preeclampsia, cesarean delivery, neonatal hypoglycemia, macrosomia, and birth trauma. For the mother, GDM significantly raises the lifetime risk of developing type 2 diabetes. Women with GDM have a 7-fold higher risk compared with those without, and research from the Diabetes Prevention Program indicates that up to 50 percent of women with GDM progress to type 2 diabetes within 5 to 10 years after delivery. These long-term consequences underscore the importance of effective management strategies during pregnancy and the postpartum period.

The economic burden of GDM is substantial. A 2020 analysis in Diabetes Care estimated that the annual cost of GDM in the United States exceeds $1.6 billion, driven by increased maternal and neonatal hospitalizations, higher rates of cesarean delivery, and long-term metabolic consequences for both mother and child. Beyond economics, the emotional toll includes increased anxiety about pregnancy outcomes, difficulty adhering to complex treatment regimens, and the psychological weight of a chronic diagnosis during what should be a celebratory time.

Current Management Strategies: Strengths and Limitations

The standard of care for GDM begins with lifestyle modifications: medical nutrition therapy (MNT) tailored to pregnancy, moderate physical activity, and self-monitoring of blood glucose. When glycemia targets are not achieved, pharmacologic intervention is required. Insulin remains the first-line pharmacological treatment due to its long safety record and lack of placental transfer. However, insulin therapy can be burdensome, requiring injections multiple times per day, frequent dose adjustments, and careful storage. Patient adherence may suffer, especially among women who are needle-phobic or have busy schedules that make multiple daily injections impractical.

In some regions, oral agents like metformin and glyburide are used off-label for GDM. Meta-analyses suggest metformin is safe and effective, with lower rates of maternal weight gain and neonatal hypoglycemia compared with insulin, but it crosses the placenta, raising concerns about long-term effects on offspring. The MiG trial (Metformin in Gestational Diabetes) showed that metformin was associated with less maternal weight gain and similar pregnancy outcomes compared with insulin, but children exposed to metformin in utero had higher BMI and central adiposity at 9 years of age in follow-up studies. Glyburide carries higher rates of maternal hypoglycemia and neonatal complications and is not recommended by many guidelines. These limitations highlight the ongoing need for alternative, more convenient, yet safe therapies for GDM that can improve both short-term pregnancy outcomes and long-term metabolic health.

Beyond pharmacotherapy, the importance of postpartum follow-up cannot be overstated. The American Diabetes Association recommends that women with GDM undergo a 75-gram OGTT at 4 to 12 weeks postpartum to assess for persistent glucose intolerance. Yet, adherence to this recommendation is poor, with studies reporting that fewer than 50 percent of women complete postpartum diabetes screening. This gap in care represents a missed opportunity for early intervention and prevention of type 2 diabetes.

The Emergence of Oral Semaglutide

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally approved as an injectable for type 2 diabetes and later for chronic weight management. In 2019, the FDA approved an oral formulation of semaglutide (Rybelsus), making it the first GLP-1 receptor agonist available in pill form. The oral version contains an absorption enhancer, SNAC (sodium N-(8-[2-hydroxybenzoyl] amino) caprylate), which facilitates transcellular absorption across the gastric mucosa and protects the peptide from degradation in the acidic stomach environment. For non-pregnant adults, oral semaglutide provides effective glycemic control and meaningful weight loss with once-daily dosing, offering a much-needed alternative to injections for patients who prefer or require oral therapy.

The PIONEER program, a series of 10 phase 3 trials, established the efficacy and safety profile of oral semaglutide across a range of patients with type 2 diabetes. In the PIONEER 1 trial, oral semaglutide 14 mg daily reduced HbA1c by 1.3 percent and body weight by 4.5 kg compared with placebo at 26 weeks. In PIONEER 2, it showed superiority to empagliflozin in glycemic control, and in PIONEER 3, it was effective across a range of background therapies. These results, published in The Lancet Diabetes & Endocrinology and other high-impact journals, have positioned oral semaglutide as a major advance in diabetes pharmacotherapy.

Mechanism of Action in the Context of Pregnancy

The pharmacodynamics of semaglutide are well-established: it binds to GLP-1 receptors, stimulating glucose-dependent insulin secretion, suppressing glucagon release, slowing gastric emptying, and promoting satiety. In a healthy pregnancy, the endogenous GLP-1 response is altered, potentially contributing to the pathophysiology of GDM. A 2017 study in The Journal of Clinical Endocrinology & Metabolism found that women with GDM had a significantly reduced incretin effect and lower GLP-1 response to oral glucose compared with women with normal glucose tolerance. Oral semaglutide could theoretically compensate for this deficiency, enhancing insulin secretion in response to meals and moderating postprandial glucose spikes. Additionally, its effect on delaying gastric emptying may reduce rapid glucose absorption, an added benefit for women with GDM who struggle with post-meal hyperglycemia.

The glucose-dependent nature of GLP-1 agonists is particularly attractive in pregnancy. Because these agents stimulate insulin secretion only when glucose levels are elevated, the risk of hypoglycemia is inherently lower compared with exogenous insulin administration. This is critical for fetal safety, as maternal hypoglycemia can reduce oxygen delivery to the fetus and cause metabolic stress. However, the effect of semaglutide on gastric emptying may also delay absorption of nutrients, which could have implications for fetal nutrient delivery and growth. This nuance underscores the need for detailed pharmacokinetic and pharmacodynamic studies in the pregnant population before clinical use can be considered.

Potential Benefits for Pregnant Women

  1. Convenience and adherence: A daily oral pill eliminates the need for injections, which is especially appealing for women who may already be anxious about needles or complex insulin regimens. Adherence to oral medications is typically higher than injectable therapies across chronic diseases, and the simplicity of once-daily dosing could reduce the cognitive and time burden on expectant mothers.
  2. Weight management: GDM is strongly linked to excess adiposity. Oral semaglutide promotes modest weight loss, which could improve maternal metabolic health and reduce the risk of GDM recurrence in future pregnancies. Pre-pregnancy obesity is the most modifiable risk factor for GDM, and achieving or maintaining a healthy weight before conception could lower GDM incidence rates.
  3. Potentially lower hypoglycemia risk: Because GLP-1 agonists work in a glucose-dependent manner, they carry a lower intrinsic risk of hypoglycemia compared with insulin or sulfonylureas, making them attractive in a population where hypoglycemia can harm both mother and fetus. The safety profile of oral semaglutide from the PIONEER program shows rates of severe hypoglycemia below 1 percent, which is favorable compared with insulin-based regimens.
  4. Cardiovascular profile: In non-pregnant populations, semaglutide has demonstrated cardioprotective effects in both cardiovascular outcomes trials (SUSTAIN 6 for injectable semaglutide) and in the PIONEER 6 trial for the oral formulation. While pregnancy-specific data are absent, improving cardiovascular risk factors during gestation may have long-term benefits for women with GDM, who are at elevated risk for future cardiovascular disease independent of diabetes progression.
  5. Potential for postpartum continuation: Women with a history of GDM are ideal candidates for diabetes prevention strategies after delivery. If oral semaglutide is found safe during pregnancy, it could seamlessly continue into the postpartum period to address both glycemic control and weight management, reducing the risk of progression to type 2 diabetes.

Safety Considerations and Knowledge Gaps

Despite these theoretical advantages, oral semaglutide is not currently approved for use during pregnancy. Animal studies with GLP-1 agonists have shown fetal anomalies at high doses, likely related to reduced maternal food intake and weight loss. In a rat study of liraglutide, another GLP-1 agonist, fetal growth restriction and skeletal abnormalities were observed at maternal exposures approximately 3 times the human exposure at the maximum recommended dose. Human data are extremely limited, with no controlled trials in pregnant women and only isolated case reports of accidental exposure during early pregnancy that have not shown clear adverse signals, but the sample size is far too small to draw conclusions. The FDA label for oral semaglutide carries a warning against use during pregnancy, advising that women of childbearing potential should use effective contraception. Therefore, any discussion of its potential role in GDM must be framed within the context of ongoing research and the need for rigorous clinical trials before any clinical deployment can be considered.

The pharmacokinetics of oral semaglutide in pregnancy are unknown. Pregnancy induces profound changes in gastrointestinal function, including delayed gastric emptying (already a known effect of GLP-1 agonists), increased gastric pH, altered hepatic blood flow, and increased renal clearance. The absorption enhancer SNAC, which is integral to oral semaglutide's bioavailability, may behave differently in the pregnant gastrointestinal tract. Furthermore, the extent of placental transfer of oral semaglutide is not characterized. While large peptide-based GLP-1 agonists are generally expected to have limited placental transfer due to their molecular size, the SNAC component could theoretically alter permeability or facilitate passage. These unknowns represent significant barriers to clinical translation and must be resolved through dedicated preclinical and phase I studies.

There is also the question of long-term fetal safety. The programmed nature of fetal development means that any perturbation of maternal metabolism, including drug-induced weight loss or altered glucose dynamics, could have lasting effects on offspring. The concept of fetal programming, as articulated by the Barker hypothesis, suggests that intrauterine exposures shape lifelong metabolic and cardiovascular health. Weight loss during pregnancy, while potentially beneficial for maternal outcomes, is generally discouraged due to concerns about fetal undernutrition. The weight loss induced by oral semaglutide, even if mild, must be carefully evaluated in this context.

Research and Evidence to Date

To date, no prospective controlled trials have evaluated oral semaglutide in pregnant women with GDM. However, several lines of evidence inform the discussion and provide a basis for future research directions.

  • Non-pregnant type 2 diabetes: The PIONEER program demonstrated that oral semaglutide is safe and effective for glycemic control and weight reduction in adults with type 2 diabetes, with gastrointestinal side effects being the most common. Nausea, vomiting, and diarrhea were reported in up to 20 percent of patients in some trials, though these effects typically diminish over time with dose escalation. For a pregnant population, tolerability is a particular concern, as pregnancy itself is associated with nausea and vomiting, and the additive effect could be problematic.
  • GDM pathophysiology: Studies show that women with GDM have reduced incretin effect and lower GLP-1 secretion. Restoring GLP-1 activity with exogenous therapy is a plausible therapeutic target. A 2021 review in Endocrine Connections highlighted GLP-1 agonists as a potential future avenue for GDM treatment, pending safety data. The review authors noted that the theoretical rationale is strong but that the evidence gap is wide, and they called for rigorous preclinical and clinical investigation before any off-label use.
  • Animal studies: Rat studies with liraglutide showed fetal growth restriction and skeletal abnormalities, likely due to maternal weight loss. However, oral semaglutide's unique absorption profile may result in different pharmacokinetics in pregnancy, including altered placental transfer. No animal studies of oral semaglutide in pregnancy models have been published to date, which represents a critical gap that must be filled before human studies can ethically proceed.
  • Accidental exposure reports: A small number of case reports describe accidental exposure to injectable semaglutide or other GLP-1 agonists during early pregnancy, often before the pregnancy was known. In these cases, pregnancy outcomes were generally unremarkable, but the data are sparse, uncontrolled, and subject to publication bias. The FDA maintains a pregnancy registry for GLP-1 agonists under the REMS program, and healthcare providers are encouraged to report any exposures to the registry to build a more robust evidence base.
  • Ongoing research: A search on ClinicalTrials.gov reveals no currently enrolling trials of oral semaglutide for GDM. However, there is growing interest among researchers, and some phase I safety studies may be on the horizon. In April 2023, the National Institute of Child Health and Human Development funded a planning grant for a multicenter consortium to investigate novel pharmacotherapies for GDM, which may include GLP-1 agonists in future protocols. Additionally, the World Health Organization has identified GDM treatment optimization as a research priority for the current decade.

Future Directions and Clinical Considerations

For oral semaglutide to become a viable option in GDM management, several critical steps must be taken. The pathway from a promising biological hypothesis to a clinically approved therapy for use in pregnancy is demanding and appropriately conservative.

  1. Pharmacokinetic and placental transfer studies: Researchers need to assess whether the drug crosses the placenta and, if so, at what rate. Animal models with oral formulations are needed before human trials can commence. Ex vivo human placental perfusion models, like those used with metformin and other drugs, could provide early data on placental transfer dynamics without exposing any living subject.
  2. Dose-finding in pregnancy: Pregnancy alters drug absorption, distribution, and clearance. The standard 3 to 14 mg once-daily doses used in non-pregnant adults may need adjustment. The glomerular filtration rate increases by up to 50 percent during pregnancy, which could accelerate drug clearance, while changes in gastric pH and transit time could affect absorption. A dedicated dose-ranging study in pregnant women with GDM would be necessary to identify the optimal therapeutic window.
  3. Long-term follow-up: Offspring exposed to semaglutide in utero would need long-term monitoring for metabolic, neurodevelopmental, and growth outcomes. Ideally, this would include standardized assessments of glucose homeostasis, body composition, cognitive function, and cardiovascular risk markers at regular intervals throughout childhood and adolescence. The lessons from the MiG trial follow-up, which revealed late metabolic effects of metformin exposure, underscore the importance of extended observation periods.
  4. Comparative effectiveness trials: If safety is established, oral semaglutide must be compared head-to-head against insulin and metformin to demonstrate non-inferiority or superiority with respect to maternal glycemic outcomes and neonatal safety. The primary endpoint in such trials should be a composite of maternal glycemic control, pregnancy outcomes (including preeclampsia, preterm birth, and birth trauma), and neonatal outcomes (including hypoglycemia, respiratory distress, and weight-for-gestational-age). Secondary endpoints should include maternal quality of life, treatment adherence, and postpartum metabolic health.
  5. Regulatory considerations: Gaining pregnancy-specific approval from the FDA or the European Medicines Agency would require a carefully designed development program, likely beginning with a pregnancy registry to accumulate safety data before moving to interventional trials. The regulatory pathway for drugs in pregnancy is challenging because of ethical concerns about exposing a vulnerable population to potential harm, but the risk-benefit calculus shifts when effective therapies for serious pregnancy conditions are lacking.

While the promise of a convenient oral agent is appealing, the principle of first, do no harm must guide any exploration of new therapies in pregnancy. Patients and clinicians should remain cautious and rely on evidence-based approaches until robust safety data are available. This does not mean research should be discouraged; on the contrary, dedicated investigation is the only path to resolving the current uncertainties. But it does mean that clinical practice should not outpace the evidence.

Clinicians caring for women with GDM can support progress by encouraging patients to enroll in pregnancy registries and by documenting any accidental medication exposures during pregnancy. Academic centers should consider building research infrastructure for pharmacologic studies in pregnancy, which currently lags far behind non-pregnant populations. Funding agencies, including the National Institutes of Health and the European Commission, have increased their focus on maternal-fetal pharmacology, but continued investment is needed.

Conclusion: A Tool for the Future, Not the Present

Oral semaglutide represents a fascinating frontier in diabetes care, and its potential extension to gestational diabetes is biologically plausible and clinically tempting. The incretin axis is disrupted in GDM, and pharmacologic restoration of GLP-1 activity could address core pathophysiologic deficits while offering the convenience of an oral agent. The PIONEER program has amply demonstrated the efficacy and safety of oral semaglutide in non-pregnant adults, and the burden of GDM worldwide demands innovation in treatment.

However, the absence of pregnancy-specific safety data, combined with theoretical risks from animal studies and known unknowns about placental transfer, pharmacokinetics, and long-term offspring outcomes, means that oral semaglutide cannot be recommended for GDM at this time. The current standard of care, lifestyle modification, monitoring, and insulin when needed, remains the safest and most effective approach for achieving glycemic targets during pregnancy and ensuring optimal neonatal outcomes. Metformin may be considered in select cases, particularly in women who decline or cannot tolerate insulin, but should be used with careful counseling about the current evidence base.

Healthcare providers should counsel women with GDM about emerging therapies in the context of research participation, not clinical practice. Women of childbearing potential who are considering semaglutide for type 2 diabetes or weight management should be counseled about effective contraception and the importance of discontinuing the drug if pregnancy is planned. With dedicated investigation, oral semaglutide may one day offer a more convenient, effective option for managing GDM, but that day has not yet arrived. Continued education, research funding, and collaborative clinical trials will be essential to turn this potential into reality, but the timeline for such progress is measured in years, not months.

For clinicians, the message is one of cautious optimism. The biology is compelling, the therapeutic need is real, and the possibility of an oral GDM therapy is worth pursuing. But until the evidence is in, the safe path for mothers and their babies remains the well-travelled road of insulin, lifestyle, and careful glycemic monitoring.

For further reading: